While human beings are born with progressive tendencies, they do face a lot of trouble in realizing them under every possible situation. This is largely due to the complicated nature of our lives. You see, if a human being has to progress on a rather consistent basis, they have no option but to answer all the questions that they are likely to find along the way, and such a requirement can get much more problematic than you think. Hence, to make the process a bit convenient, we would develop certain avenues around us. One of these avenues is going to be technology. Technology stands out from the rest not just because of its ingenious skill-set. Instead, it also has a lot with how the creation has managed to impact each and every area across our spectrum, including a highly-critical healthcare sector. After starting out amid some serious doubt, technology and healthcare link-up has now leveled up to become a true force in its own right. In fact, it is still growing at an outright breakneck pace, and a recent funding proves that big time.
Hello Heart, the digital therapeutic that focuses on heart disease and hypertension, has successfully secured over $70 million in Series D financing. According to certain reports, the round was led by growth equity firm, Stripes. Taking the company’s total lot to $138 million, the newly-raised cash will be used towards the expansion of its digital solution. In a more specific sense, it will spell the addition of new metrics like cholesterol tracking and an expanded digital coaching element.. Talk about Hello Heart’s digital solution, it uses artificial intelligence and behavioral science to encourage users in terms of making lifestyle changes that encourage a better cardiac health. While the company has been on an upwards trajectory since starting out in 2013, the growth spurt would reach another gear during the pandemic. Notably enough, Hello Heart has doubled its clientele in the last 3 months alone, with many Fortune 500 companies now joining the pack.
“We are the only solution that focuses solely on heart health that has peer-reviewed studies with strong clinical outcomes and validated cost savings,” said Maayan Cohen, co-founder and CEO of Hello Heart “There are solutions on the market that offer chronic disease management, including hypertension, but they lack the focus on heart, which is the leading cause of death and most costly disease.”
